linjc16/ctgov huggingface dataset:
Repair or Not Repair Pronator Quadratus in the Volar Plating of Distal Radial Fracture Are Functional Outcomes Differ ?

Study Overview
=================
Brief Summary
-----------------
The theoretical benefits of the repair of the pronator quadratus include flexor tendon protection, remain of the normal pronation-supination range of motion (ROM) and strength, and keeping the stable DRUJ. Repair or not repair pronator quadratus in the volar plating of distal radial fracture-Are functional outcomes differ?

Detailed Description
-----------------
In the operation of distal radial fractures, the volar plating techniques become popular. During the surgical approach, the pronator quadratus (PQ) muscle needs split or full-thickness strip to exposure the fracture site and facilitate the instrumentation of the plate. Generally, the PQ would be repaired. Sometimes, the PQ is damaged by the fracture fragment so severely that it is difficult to repair the PQ. However, there is few reviews paper to discuss the consequence of the unrepaired or repaired PQ and the AAOS guideline1 of the treatment of distal radial fracture in 2009 did not even list the management of the PQ. The function of the PQ includes pronation and stability of the distal radial-ulnar joint (DRUJ). According to the study, the elimination of PQ function will cause a significant decrease in pronation torque, which is supposed to affect the function of the wrist in the daily life. The theoretical benefits of the repair of the pronator quadratus include flexor tendon protection3,4, remain of the normal pronation-supination range of motion (ROM) and strength, and keeping the stable DRUJ.

Official Title
-----------------
Repair or Not Repair Pronator Quadratus in the Volar Plating of Distal Radial Fracture-Are Functional Outcomes Differ ?

Conditions
-----------------
Distal Radius Fracture

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ≧ 20 or ≦ 80-years-old adult patients Cooperative to evaluation Distal radial fracture, fresh, single fracture Volar plating Exclusion Criteria: < 20 or > 80-years-old patients Uncooperative adult, such as dementia Old fracture, more than 1 Week Multiple fractures Pathological fracture Surgery other then volar plating

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Pronator quadratus, distal radius fracture, volar plating
Predictability of Thromboelastography Parameters in Severe Post Partum Hemorrhage

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to determine if thromboelastography parameters can be predictive of severe post partum hemorrhage.

Official Title
-----------------
Predictability of Thromboelastography Parameters in Severe Post Partum Hemorrhage : a Retrospective Study

Conditions
-----------------
Post Partum Hemorrhage

Intervention / Treatment
-----------------
* Diagnostic Test: thromboelastography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Women presenting with a post partum hemorrhage needing sulprostone infusion during third trimester of pregnancy Exclusion Criteria: known coagulation disorders

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Post Partum Hemorrhage<br>Patients presenting with a post partum hemorrhage. A thromboelastography analysis is realized at discretion of the anesthesiologist in charge | Diagnostic Test: thromboelastography<br>* TEG5000® : Kaolin and Functional Fibrinogen tests on native blood sample<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Calculated blood loss | Calculated blood loss at 24 hours after delivery (Sum of the volume of blood transfused and the volume of blood loss calculated by the decrease in hematocrit.) | during the 24 hours after delivery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
thromboelastography
A Prospective Study to Examine the Need to Adjust the Dose of Apixaban When Used in Atrial Fibrillation and Obesity

Study Overview
=================
Brief Summary
-----------------
A prospective cohort study to determine whether a high body weight (BMI equal to or greater than 35 kg / m 2) has an effect on anticoagulant Apixaban level in the blood of patients with atrial fibrillation.

Official Title
-----------------
A Prospective Cohort Study to Examine the Need to Adjust the Dose of Anticoagulant Apixaban When Used in Patients With Atrial Fibrillation and Obesity

Conditions
-----------------
Anticoagulant, Apixaban, Obesity

Intervention / Treatment
-----------------
* Diagnostic Test: Anti Xa levels


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - hospitalized Patients on Steady State level of Apixaban, based on the data given in the hospital ward . A level of Steady State is received within two days of treatment. Exclusion Criteria: Anasarca acute renal failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Body mass index below 35<br> | Diagnostic Test: Anti Xa levels<br>* one Blood sample<br>|
| Body mass index 35 and above<br> | Diagnostic Test: Anti Xa levels<br>* one Blood sample<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anti Xa level of patients with atrial fibrillation and obesity while treatment of Apixaban. |  | 6 month |
A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia

Study Overview
=================
Brief Summary
-----------------
This is a multicenter, open-label, adaptive, repeat-dose study to evaluate the safety, tolerability, and pharmacokinetics of iloperidone long-acting injection (LAI) in patients with schizophrenia.

Official Title
-----------------
An Open-label, Adaptive, Repeat-dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Iloperidone Long-acting Injection (LAI) in Patients With Schizophrenia

Conditions
-----------------
Schizophrenia

Intervention / Treatment
-----------------
* Drug: Iloperidone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Willing and able to provide written informed consent. Male or female patients 18 to 65 years of age (inclusive). Clinical diagnosis of schizophrenia according to the Diagnostic and Statistical Manual of Mental Disorder (DSM-5) for at least 1 year. Symptomatically stable within the past two months. Exclusion Criteria: Use of other investigational drugs at the time of enrollment, or within 30 days or 5 half-lives of enrollment, whichever is longer. Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs. Pregnant or nursing (lactating) women. A positive test for drugs of abuse.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Iloperidone<br> | Drug: Iloperidone<br>* oral tablet, long-acting injection<br>* Other names: VYV-683;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetics of iloperidone and its metabolites following repeat-dosing of iloperidone given as a long-acting injection. | As measured by plasma concentrations. | 24 weeks | 
| Assessment of safety and tolerability of repeat-dosing of iloperidone given as a long-acting injection. | As measured by spontaneous reporting of adverse events (AEs). | 24 weeks |
Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions

Study Overview
=================
Brief Summary
-----------------
The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fasted conditions

Official Title
-----------------
A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions

Conditions
-----------------
Dry Mouth

Intervention / Treatment
-----------------
* Drug: Cevimeline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - No clinically significant abnormal findings on the physical examination, medical history, or clinical laboratory results during screening Exclusion Criteria: Positive test for HIV, Hepatitis B, or Hepatitis C. Treatment with known enzyme altering drugs. History of allergic or adverse response to cevimeline or any comparable or similar product.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 45 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Cevimeline<br>Single Dose 30 mg Capsule | Drug: Cevimeline<br> <br> * Other names: Evoxac;|
| Active Comparator: Evoxac<br>Single dose 30 mg capsule | Drug: Cevimeline<br> <br> * Other names: Evoxac;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| bioequivalence determined by statistical comparison Cmax comparison of the pharmacokinetic parameters | The comparison of the pharmacokinetic parameters of the test and reference products | 33 Days |
Tau PET Imaging in Atypical Dementias

Study Overview
=================
Brief Summary
-----------------
The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techniques.

Official Title
-----------------
Tau PET Imaging in Atypical Dementias

Conditions
-----------------
Primary Progressive Aphasia With Suspected Alzheimer's Disease

Intervention / Treatment
-----------------
* Drug: 18F-AV-1451
* Device: PET


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Must have primary progressive aphasia Exclusion Criteria: Pregnancy Breastfeeding Receiving radiation clinically

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AV-1451 Recipients<br>Participants in this arm of the study will all receive an injection of 10 Mci of AV-1451 and then be scanned in a PET scanner for brain imaging. | Drug: 18F-AV-1451<br> <br> * Other names: AV-1451;Device: PET<br>* PET scanner for brain imaging<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Tau levels in PPA participants | Tau deposition as measured by 18F-AV-1451 standardized uptake value ratio (SUVR) in cortical and medial temporal regions. | 2 years |
Mucinex® for Treatment of Filamentary Keratitis

Study Overview
=================
Brief Summary
-----------------
It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.

Detailed Description
-----------------
The study is aimed to determine if oral administration of Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis. Subjects will be instructed to take 600 mg tablets of extended release Mucinex® twice a day (total dose is 1.2 g/day) for 4 weeks.

Official Title
-----------------
Mucinex® for Treatment of Filamentary Keratitis

Conditions
-----------------
Filamentary Keratitis

Intervention / Treatment
-----------------
* Drug: Mucinex®


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with filamentary keratitis 18 years and older Exclusion Criteria: Active ocular surface infection of any type Recent ocular surgery (<30 days) history of nephrolithiasis as Mucinex® has been associated in rare cases of development of kidney stones Schirmer's test<3mm History of hypersensitivity to Mucinex® Concurrent eye disease requiring immediate initiation of a new treatment (e.g. topical steroids) restriction for water intake can exacerbate the risk of nephrolithiasis.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Other: Mucinex<br>600 mg of Mucinex 2 times a day. | Drug: Mucinex®<br>* Mucinex®<br>* Other names: Guaifenesin;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in Number of Corneal Filaments | Change was calculated as the value after receiving treatment with guaifenesin for 4 weeks minus the value at baseline. | baseline (day 1) and week 4 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in OSDI Score | Change was calculated as the value after receiving treatment with guaifenesin for 4 weeks minus the value at baseline. Total score ranges from 0-100. Lower OSDI scores means subjects are experiencing low ocular discomfort. High OSDI scores means subjects are experiencing high ocular discomfort. | baseline (day 1) and week 4 |
Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Live in Patients With Essential Hypertension

Study Overview
=================
Brief Summary
-----------------
Study to assess the effect of Telmisartan on diastolic and systolic blood pressure and to establish the effect on patient's quality of life scores.

Official Title
-----------------
An Open-label Evaluation of the Effectiveness of MICARDIS® (Telmisartan) on Blood Pressure Control and Quality of Life in Patients With Essential Hypertension The MICARDIS COMMUNITY ACCESS TRIAL (MicCAT)

Conditions
-----------------
Hypertension

Intervention / Treatment
-----------------
* Drug: Low dose of telmisartan
* Drug: High dose of telmisartan


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with Stage I essential Hypertension (diastolic blood pressure 90-99 mmHg, and/or systolic blood pressure 140-159 mmHg) Signed informed consent form Exclusion Criteria: - Females of childbearing potential

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 93 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Telmisartan low dose<br> | Drug: Low dose of telmisartan<br> <br> |
| Experimental: Telmisartan high dose<br> | Drug: High dose of telmisartan<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in diastolic blood pressure |  | Pre-dose, up to 6 weeks after start of treatment | 
| Change in systolic blood pressure |  | Pre-dose, up to 6 weeks after start of treatment | 
| Changes from baseline in the quality of life (QOL) scores by patient self-assessment |  | Pre-dose, 6 weeks after start of treatment | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of blood pressure control rate |  | Up to 6 weeks after start of treatment | 
| Assessment of systolic blood pressure response rate |  | Up to 6 weeks after start of treatment | 
| Assessment of diastolic blood pressure response rate |  | Up to 6 weeks after start of treatment | 
| Change from baseline in pulse pressure |  | Pre-dose, up to 6 weeks after start of treatment | 
| Number of patients with adverse events |  | Up to 6 weeks |
Longitudinal Follow up of Patients With Pleural Effusion

Study Overview
=================
Brief Summary
-----------------
This study aims to evaluate the clinical course of patients diagnosed with pleural effusion and determine various clinical factors and biomarkers associated that can predict the diagnosis and clinical outcome and prognosis of patients with pleural effusion due to specific causes.

Detailed Description
-----------------
Patients who presented to Seoul National University Bundang Hospital with pleural effusion would be recruited. Pleural fluid and blood samples would be collected. All patients will receive routine diagnostic procedures and medical care and treatments according to the diagnosis; the original cancer if diagnosed with malignant effusion, and managements for pleural effusion control. Patients would be observed for the clinical course and prognosis up to 3 years without any interventions caused by this study.

Official Title
-----------------
Longitudinal Follow up of Patients With Pleural Effusion in South Korea

Conditions
-----------------
Pleural Effusion, Malignant, Prognosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients presented with pleural effusion Patients who undergo thoracentesis and fluid analysis for diagnosis and management Exclusion Criteria: Patients who refuse to be enrolled
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | Mortality | From date of diagnosis of malignant pleural effusion until the date of death, assessed up to 36 months. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Disease progression | Progression of original malignancy or new metastasis occured | From date of diagnosis of malignant pleural effusion until the date of first documented disease progression, assessed up to 36 months. |
Comparison of Different Up-dosing Schedules With Osiris

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare different up-dosing schedules with Osiris.

Conditions
-----------------
Allergic Rhinitis

Intervention / Treatment
-----------------
* Drug: OSIRIS
* Drug: OSIRIS other concentration 1
* Drug: OSIRIS other concentration 2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: history of grass pollen allergy Positive SPT to grass Positive IgE to grass Exclusion Criteria: uncontrolled and severe asthma

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: OSIRIS<br> | Drug: OSIRIS<br>* OSIRIS current practice<br>|
| Experimental: OSIRIS other concentration 1<br> | Drug: OSIRIS other concentration 1<br>* OSIRIS new concentration 1<br>|
| Experimental: OSIRIS other concentration 2<br> | Drug: OSIRIS other concentration 2<br>* OSIRIS new concentration 2<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluate the tolerability of different up-dosing schedules |  | 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| patient's satisfaction |  | 30 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Rhinitis, Allergic, Immunotherapy